Literature DB >> 7478579

PU.1 (Spi-1) autoregulates its expression in myeloid cells.

H Chen1, D Ray-Gallet, P Zhang, C J Hetherington, D A Gonzalez, D E Zhang, F Moreau-Gachelin, D G Tenen.   

Abstract

PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478579

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

1.  Do lampreys have lymphocytes? The Spi evidence.

Authors:  S Shintani; J Terzic; A Sato; M Saraga-Babic; C O'hUigin; H Tichy; J Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Macrophage-specific gene expression: current paradigms and future challenges.

Authors:  David R Greaves; Siamon Gordon
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

Review 3.  Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia.

Authors:  Steffen Koschmieder; Frank Rosenbauer; Ulrich Steidl; Bronwyn M Owens; Daniel G Tenen
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

4.  C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment.

Authors:  Christine Yeamans; Dehua Wang; Ido Paz-Priel; Bruce E Torbett; Daniel G Tenen; Alan D Friedman
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

5.  The conserved 5'-untranslated leader of Spi-1 (PU.1) mRNA is highly structured and potently inhibits translation in vitro but not in vivo.

Authors:  J O Hensold; C A Stratton; D Barth
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

6.  The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation.

Authors:  A Rosa; M Ballarino; A Sorrentino; O Sthandier; F G De Angelis; M Marchioni; B Masella; A Guarini; A Fatica; C Peschle; I Bozzoni
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

7.  Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1.

Authors:  Michael Papetti; Arthur I Skoultchi
Journal:  Mol Cancer Res       Date:  2007-10       Impact factor: 5.852

8.  PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation.

Authors:  Hitoshi Yoshida; Hitoshi Ichikawa; Yusuke Tagata; Takuo Katsumoto; Kazunori Ohnishi; Yukihiro Akao; Tomoki Naoe; Pier Paolo Pandolfi; Issay Kitabayashi
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

9.  PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element.

Authors:  Alexander K Ebralidze; Florence C Guibal; Ulrich Steidl; Pu Zhang; Sanghoon Lee; Boris Bartholdy; Meritxell Alberich Jorda; Victoria Petkova; Frank Rosenbauer; Gang Huang; Tajhal Dayaram; Johanna Klupp; Karen B O'Brien; Britta Will; Maarten Hoogenkamp; Katherine L B Borden; Constanze Bonifer; Daniel G Tenen
Journal:  Genes Dev       Date:  2008-08-01       Impact factor: 11.361

10.  Pharmacological inhibition of the transcription factor PU.1 in leukemia.

Authors:  Iléana Antony-Debré; Ananya Paul; Joana Leite; Kelly Mitchell; Hye Mi Kim; Luis A Carvajal; Tihomira I Todorova; Kenneth Huang; Arvind Kumar; Abdelbasset A Farahat; Boris Bartholdy; Swathi-Rao Narayanagari; Jiahao Chen; Alberto Ambesi-Impiombato; Adolfo A Ferrando; Ioannis Mantzaris; Evripidis Gavathiotis; Amit Verma; Britta Will; David W Boykin; W David Wilson; Gregory Mk Poon; Ulrich Steidl
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.